SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Syngene International Ltd

BSE: 539268 NSE: SYNGENE ISIN: INE398R01022
  |   Sector:  Miscellaneous   |   Industry:  Business Support

Snapshot

Q.1 Is Syngene International Ltd a good quality company?
Syngene International Ltd is a quality company, based on a 10 year financial track record .
Q.2 Is Syngene International Ltd undervalued or overvalued?
Syngene International Ltd appears Overvalued , as its key valuation ratios are below with their past averages.
Q.3 Is Syngene International Ltd a good buy now?
Syngene International Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall . However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Gross Profit margin of Syngene International Ltd?
Syngene International Ltd Gross profit margin which is the profit after deduction of direct costs, is 28.3% for FY-2025 , which is above its 5 year median of 0% , indicating increasing margins.
Q.2 Operating Profit Margin of Syngene International Ltd?
Syngene International Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 27.32% for FY-2025 , which is above its 5 year median of 0% indicating increasing margins.
Q.3 Net Profit Margin of Syngene International Ltd?
Syngene International Ltd Net Profit Margin is 13.87% for FY-2025 , is above with its 5 year median of 0%, indicating increasing margins.
Q.4 Return on Asset of Syngene International Ltd?
Syngene International Ltd Return on Asset is 7.7(x), which is above its 5 year historical median of 0(x), indicating improved asset utilization efficiency.
Q.5 Return on Equity (ROE) of Syngene International Ltd?
Syngene International Ltd Return on equity is 10.65% for FY-2025 , which is above its historical median of 0%, indicating the business is making better use of its shareholders capital.
Q.6 Return on capital employed (ROCE) of Syngene International Ltd?
Syngene International Ltd Return on capital employed is 14.39% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 11.25%, indicating value creation .
Q.7 Cash conversion cycle of Syngene International Ltd?
Syngene International Ltd Cash conversion cycle is 24 , above its historical median of 0 , indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Q.8 Debt to Equity ratio of Syngene International Ltd?
Syngene International Ltd Debt-to-Equity ratio is 0.02 , which is above with the industry average of 0 , indicating higher debt levels in the industry.
Q.9 Debt to cash flow from operations of Syngene International Ltd?
Syngene International Ltd Debt to cash flow from operations is 0.09 , which is at a healthy level, indicating the business is able to service its debt comfortably.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Syngene International Ltd?
Promoters hold 52.68% of the Syngene International Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Syngene International Ltd vs industry peers?
Syngene International Ltd revenue CAGR is 10.89% , compared to the industry median CAGR of 19.49% , indicating slower growth and losing its market share.

Valuation & price assessment

Q.1 Stock return of Syngene International Ltd over the last decade?
Over the last 9 years, the stock has delivered a CAGR of 8.5% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 8.5% -6.3% -12.8% -42.3%
Q.3 Valuation ratios of Syngene International Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 49.26 48.78 29.41
Price to Book 3.52 8.84 2.54
Price to Sales 4.78 9.64 4.88
EV to EBITDA 17.66 28.43 11.31

Check more companies

1. Prime Focus
2. Sagility
3. Syngene Internation.
4. International Gemolo
5. Indegene
6. NESCO
7. Latent View Analytic
8. Just Dial
9. CMS Info Systems
10. Sun Pharma Adv. Res
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×